Welcome to our dedicated page for Nuvation Bio news (Ticker: NUVB), a resource for investors and traders seeking the latest updates and insights on Nuvation Bio stock.
Nuvation Bio Inc. reports news as a global oncology company developing and commercializing targeted cancer therapies. Its updates center on IBTROZI® (taletrectinib), an oral, CNS-active, selective next-generation ROS1 inhibitor approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, as well as regulatory submissions, clinical data from TRUST studies, guideline inclusion, and commercialization activity.
Company news also covers safusidenib, a brain-penetrant IDH1 inhibitor for IDH1-mutant glioma, and Nuvation Bio's drug-drug conjugate program. Recurring corporate items include licensing and collaboration arrangements, product-rights updates, investor conference participation, operating results, financial results, capital-structure disclosures, and governance matters.
Nuvation Bio (NYSE: NUVB) reported full exercise of underwriters’ $37.5 million greenshoe option in its 0.75% Convertible Senior Notes due 2032 offering. Total aggregate principal reached $287.5 million. Nuvation Bio expects net proceeds of about $277.6 million after fees and expenses.
The company entered additional capped call transactions with a $10.4580 cap price, an 80% premium to the June 25, 2026 share price, spending approximately $2.2 million. Remaining proceeds are earmarked for general corporate purposes, including working capital and operating needs.
Nuvation Bio (NYSE: NUVB) announced that the UK MHRA has validated the Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer (NSCLC). The MAA, filed via the International Recognition Procedure, will now undergo full review.
The submission is based on pivotal Phase 2 TRUST-I and TRUST-II data. A separate MAA is under review by the European Medicines Agency, and additional filings are planned for Canada and other Eisai-licensed regions. Taletrectinib already has approvals for ROS1+ NSCLC in the US, Japan and China.
Nuvation Bio (NYSE: NUVB) priced an upsized underwritten offering of $250.0 million 0.75% Convertible Senior Notes due 2032, increased from $200.0 million, with a $37.5 million over-allotment option.
Net proceeds are estimated at $241.2–$277.6 million, mainly for capped calls, loan repayment, and general corporate purposes.
Nuvation Bio (NYSE: NUVB) plans an underwritten offering of $200 million Convertible Senior Notes due 2032, with a $30 million over-allotment option. The unsecured notes will pay semiannual interest and may be settled in cash, Class A common stock, or both upon conversion.
According to Nuvation Bio, net proceeds are expected to fund capped call transactions, fully repay its senior secured loan, and support general corporate purposes. Capped calls are intended to limit potential dilution or extra cash payments upon note conversion, subject to a cap.
Nuvation Bio (NYSE: NUVB) announced that Founder, President and CEO David Hung and CFO Philippe Sauvage will join a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:55 a.m. ET in New York.
A live webcast and 90-day archive will be available on the company’s investor relations website.
Nuvation Bio (NYSE: NUVB) reported new patient-reported outcomes from the Phase 2 TRUST-II study of IBTROZI (taletrectinib) in advanced ROS1-positive NSCLC. Among 69 patients, 88% showed improved or stable global quality-of-life at first assessment, with cognitive function and key symptoms like cough and shortness of breath generally improving or remaining stable over time.
IBTROZI is FDA-approved in the US for locally advanced or metastatic ROS1+ NSCLC, approved in Japan and China, has a US sNDA under review with a target action date of January 4, 2027, and an EMA MAA validated in Europe. Results will be presented at ASCO 2026.
Nuvation Bio (NYSE: NUVB) announced a collaboration with Thermo Fisher Scientific for U.S.-based manufacturing of IBTROZI (taletrectinib), for advanced or metastatic ROS1-positive non-small cell lung cancer. Process tech transfer, product introduction, and an NDA supplement for the manufacturing transition have been completed to help secure drug supply.
Nuvation Bio (NYSE: NUVB) announced FDA acceptance of a supplemental NDA for IBTROZI (taletrectinib) in advanced ROS1-positive NSCLC, with a target action date of January 4, 2027. The submission adds 10 months of follow-up (August 2025 cutoff) from TRUST-I and TRUST-II.
Key efficacy updates: TRUST-I TKI-naïve mDOR 49.7 months and mPFS 49.6 months; TRUST-II TKI-pretreated mDOR 19.4 months. Safety remained consistent with prior reports.
Nuvation Bio (NYSE: NUVB) announced that CEO David Hung, M.D., and CFO Philippe Sauvage will participate in multiple investor conferences in May 2026, including Bank of America, H.C. Wainwright BioConnect, RBC Capital Markets, and TD Cowen oncology summit.
Live webcasts will be available on the company's Investor Relations website, with archived recordings posted for 90 days after each event.
Nuvation Bio (NYSE: NUVB) reported Q1 2026 results and corporate updates on May 4, 2026. Key points: IBTROZI net product revenue $18.5M, collaboration and license revenue $64.7M, and cash, cash equivalents, and marketable securities of $533.7M as of March 31, 2026. Clinical updates include pooled TRUST-I/II data showing a TKI-naïve cORR 89.8%, mDOR 49.7 months and mPFS 46.1 months; EMA MAA validation in Europe; acquisition of global safusidenib rights; SIGMA Phase 3 ongoing.